Research Area: Neurological Disease Biological Activity: Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is a selective noradrenalin re-uptake inhibitor and a tetracyclic antidepressant. Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) acts primarily by potentiation of central adrenergic synapses by blocking reuptake of norepinephrine at nerve endings. The pharmacologic action of Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is thought to be responsible for the drug’s antidepressant and anxiolytic effects. Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is also effective for the relief of anxiety associated with depression. [1][2]
Harmful (Xn)